



INFLAMMATORY SKIN DISEASES (OTHER THAN ATOPIC DERMATITIS & PSORIASIS)

## WELLS' SYNDROME AND ASSOCIATION WITH IMMUNOMODULATORS: A CASE REPORT AND LITERATURE REVIEW

*O Last<sup>(1)</sup> - M Rozenblat<sup>(2)</sup> - S.e Gur<sup>(3)</sup>*

*Soroka Hospital, Dermatology, Beer Sheva, Israel<sup>(1)</sup> - Ha-emek Medical Center, Dermatology, Afula, Israel<sup>(2)</sup> - Soroka Hospital, Dermatology, Beer Sheva, Israel<sup>(3)</sup>*

**Background:** Wells' syndrome is a well-known infrequent inflammatory eosinophilic dermatosis first described in 1971 by Wells. The etiology for Wells' syndrome is unknown; however, multiple etiologies have been described, among them are drugs. We sought to investigate the role of immunomodulatory medications.

**Observation:** We present here a 58-year-old patient with Wells' syndrome that occurred close to initiation of treatment with ustekinumab.

**Key message:** A comprehensive literature search for the association between immunomodulators and Wells' syndrome using PubMed and Medline found 4 cases with association to TNF-alpha inhibitors and 3 cases associated with interferons.

To the best of our knowledge, this is the first case suggesting interleukin 12/23 inhibitor agent ustekinumab as a triggering factor for Wells' syndrome. Based on limited data it is suggested that immunomodulators might play different roles in Wells' syndrome, acting as triggering factors on one hand and maybe used as possible treatments on the other.

